vs
Jack Henry & Associates（JKHY）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $619.3M、Jack Henry & Associatesの約1.2倍）。Jack Henry & Associatesの純利益率が高く（20.1% vs 12.7%、差は7.4%）。Jack Henry & Associatesの前年同期比売上増加率が高い（7.9% vs 5.9%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $131.4M）。過去8四半期でRevvityの売上複合成長率が高い（9.0% vs 7.2%）
Jack Henry & Associatesは1976年設立の米国金融テクノロジー企業で、主にコミュニティバンクや信用組合を対象に金融テクノロジー関連サービスや決済処理サービスを提供している。また地域銀行・信用組合のリスク管理、規制申告支援、オンラインバンキングサービスの最適化や機能強化も手がけている。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
JKHY vs RVTY — 直接比較
損益計算書 — Q2 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $619.3M | $772.1M |
| 純利益 | $124.7M | $98.4M |
| 粗利率 | 43.3% | — |
| 営業利益率 | 25.7% | 14.5% |
| 純利益率 | 20.1% | 12.7% |
| 売上前年比 | 7.9% | 5.9% |
| 純利益前年比 | 27.4% | 3.9% |
| EPS（希薄化後） | $1.72 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $619.3M | $772.1M | ||
| Q3 25 | $644.7M | $698.9M | ||
| Q2 25 | $615.4M | $720.3M | ||
| Q1 25 | $585.1M | $664.8M | ||
| Q4 24 | $573.8M | $729.4M | ||
| Q3 24 | $601.0M | $684.0M | ||
| Q2 24 | $559.9M | $691.7M | ||
| Q1 24 | $538.6M | $649.9M |
| Q4 25 | $124.7M | $98.4M | ||
| Q3 25 | $144.0M | $46.7M | ||
| Q2 25 | $127.6M | $53.9M | ||
| Q1 25 | $111.1M | $42.2M | ||
| Q4 24 | $97.8M | $94.6M | ||
| Q3 24 | $119.2M | $94.4M | ||
| Q2 24 | $101.1M | $55.4M | ||
| Q1 24 | $87.1M | $26.0M |
| Q4 25 | 43.3% | — | ||
| Q3 25 | 45.9% | 53.6% | ||
| Q2 25 | 44.1% | 54.5% | ||
| Q1 25 | 41.8% | 56.5% | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 42.9% | 56.3% | ||
| Q2 24 | 41.5% | 55.7% | ||
| Q1 24 | 39.1% | 54.6% |
| Q4 25 | 25.7% | 14.5% | ||
| Q3 25 | 28.5% | 11.7% | ||
| Q2 25 | 25.3% | 12.6% | ||
| Q1 25 | 23.7% | 10.9% | ||
| Q4 24 | 21.4% | 16.3% | ||
| Q3 24 | 25.2% | 14.3% | ||
| Q2 24 | 22.4% | 12.4% | ||
| Q1 24 | 20.8% | 6.8% |
| Q4 25 | 20.1% | 12.7% | ||
| Q3 25 | 22.3% | 6.7% | ||
| Q2 25 | 20.7% | 7.5% | ||
| Q1 25 | 19.0% | 6.4% | ||
| Q4 24 | 17.1% | 13.0% | ||
| Q3 24 | 19.8% | 13.8% | ||
| Q2 24 | 18.1% | 8.0% | ||
| Q1 24 | 16.2% | 4.0% |
| Q4 25 | $1.72 | $0.86 | ||
| Q3 25 | $1.97 | $0.40 | ||
| Q2 25 | $1.75 | $0.46 | ||
| Q1 25 | $1.52 | $0.35 | ||
| Q4 24 | $1.34 | $0.77 | ||
| Q3 24 | $1.63 | $0.77 | ||
| Q2 24 | $1.39 | $0.45 | ||
| Q1 24 | $1.19 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $28.2M | $919.9M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $2.2B | $7.3B |
| 総資産 | $3.1B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $28.2M | $919.9M | ||
| Q3 25 | $36.2M | $931.4M | ||
| Q2 25 | $102.0M | $991.8M | ||
| Q1 25 | $39.9M | $1.1B | ||
| Q4 24 | $25.7M | $1.2B | ||
| Q3 24 | $43.2M | $1.2B | ||
| Q2 24 | $38.3M | $2.0B | ||
| Q1 24 | $27.3M | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $60.0M | — | ||
| Q1 24 | $250.0M | — |
| Q4 25 | $2.2B | $7.3B | ||
| Q3 25 | $2.2B | $7.4B | ||
| Q2 25 | $2.1B | $7.6B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $2.0B | $7.7B | ||
| Q3 24 | $1.9B | $7.9B | ||
| Q2 24 | $1.8B | $7.9B | ||
| Q1 24 | $1.8B | $7.8B |
| Q4 25 | $3.1B | $12.2B | ||
| Q3 25 | $3.0B | $12.1B | ||
| Q2 25 | $3.0B | $12.4B | ||
| Q1 25 | $2.9B | $12.4B | ||
| Q4 24 | $2.9B | $12.4B | ||
| Q3 24 | $2.9B | $12.8B | ||
| Q2 24 | $2.9B | $13.4B | ||
| Q1 24 | $2.8B | $13.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.03× | — | ||
| Q1 24 | 0.14× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $152.7M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $131.4M | $161.8M |
| FCFマージンFCF / 売上 | 21.2% | 21.0% |
| 設備投資強度設備投資 / 売上 | 3.4% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 1.22× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $654.2M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $152.7M | $182.0M | ||
| Q3 25 | $120.6M | $138.5M | ||
| Q2 25 | $327.1M | $134.3M | ||
| Q1 25 | $107.8M | $128.2M | ||
| Q4 24 | $89.6M | $174.2M | ||
| Q3 24 | $116.9M | $147.9M | ||
| Q2 24 | $231.8M | $158.6M | ||
| Q1 24 | $97.6M | $147.6M |
| Q4 25 | $131.4M | $161.8M | ||
| Q3 25 | $111.7M | $120.0M | ||
| Q2 25 | $314.9M | $115.5M | ||
| Q1 25 | $96.1M | $112.2M | ||
| Q4 24 | $73.0M | $149.8M | ||
| Q3 24 | $104.1M | $125.6M | ||
| Q2 24 | $208.0M | $136.6M | ||
| Q1 24 | $87.7M | $129.7M |
| Q4 25 | 21.2% | 21.0% | ||
| Q3 25 | 17.3% | 17.2% | ||
| Q2 25 | 51.2% | 16.0% | ||
| Q1 25 | 16.4% | 16.9% | ||
| Q4 24 | 12.7% | 20.5% | ||
| Q3 24 | 17.3% | 18.4% | ||
| Q2 24 | 37.2% | 19.7% | ||
| Q1 24 | 16.3% | 20.0% |
| Q4 25 | 3.4% | 2.6% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 2.9% | 3.4% | ||
| Q3 24 | 2.1% | 3.3% | ||
| Q2 24 | 4.2% | 3.2% | ||
| Q1 24 | 1.8% | 2.7% |
| Q4 25 | 1.22× | 1.85× | ||
| Q3 25 | 0.84× | 2.97× | ||
| Q2 25 | 2.56× | 2.49× | ||
| Q1 25 | 0.97× | 3.03× | ||
| Q4 24 | 0.92× | 1.84× | ||
| Q3 24 | 0.98× | 1.57× | ||
| Q2 24 | 2.29× | 2.87× | ||
| Q1 24 | 1.12× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
JKHY
| Processing | $273.5M | 44% |
| Private Public Cloud | $202.7M | 33% |
| On Premise Support | $79.0M | 13% |
| Product Deliveryand Service | $64.1M | 10% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
